Yorktown Management & Research Co Inc continued to hold its position in shares of Astrazeneca PLC (NYSE:AZN) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,000 shares of the company’s stock at the end of the second quarter. Yorktown Management & Research Co Inc’s holdings in Astrazeneca PLC were worth $341,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Meeder Asset Management Inc. acquired a new position in shares of Astrazeneca PLC during the second quarter worth about $105,000. Salem Investment Counselors Inc. acquired a new position in shares of Astrazeneca PLC during the first quarter worth about $107,000. Tower Research Capital LLC TRC boosted its position in shares of Astrazeneca PLC by 3,782.0% during the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after buying an additional 3,782 shares during the period. Parallel Advisors LLC boosted its position in shares of Astrazeneca PLC by 27.1% during the first quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after buying an additional 964 shares during the period. Finally, Bronfman E.L. Rothschild L.P. boosted its position in shares of Astrazeneca PLC by 71.2% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after buying an additional 1,769 shares during the period. 14.18% of the stock is owned by institutional investors.

Shares of Astrazeneca PLC (AZN) traded down 0.28% during midday trading on Friday, hitting $32.53. The company’s stock had a trading volume of 3,100,668 shares. The firm has a market cap of $82.37 billion, a P/E ratio of 21.34 and a beta of 0.74. The stock’s 50 day moving average is $30.20 and its 200-day moving average is $31.74. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The company had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same period last year, the business earned $0.83 EPS. The business’s quarterly revenue was down 9.9% on a year-over-year basis. Equities analysts predict that Astrazeneca PLC will post $1.90 EPS for the current fiscal year.

The business also recently disclosed a None dividend, which was paid on Monday, September 11th. Investors of record on Friday, August 11th were paid a $0.44 dividend. This represents a dividend yield of 2.98%. The ex-dividend date was Wednesday, August 9th. Astrazeneca PLC’s payout ratio is 44.92%.

Several research firms have recently weighed in on AZN. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. BidaskClub cut Astrazeneca PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. BMO Capital Markets assumed coverage on Astrazeneca PLC in a report on Wednesday, September 6th. They set an “outperform” rating and a $38.00 target price on the stock. Cowen and Company reiterated a “hold” rating and set a $34.00 target price on shares of Astrazeneca PLC in a report on Friday, July 28th. Finally, Morgan Stanley lowered Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Astrazeneca PLC has an average rating of “Hold” and a consensus target price of $33.60.

COPYRIGHT VIOLATION NOTICE: “Astrazeneca PLC (AZN) Holdings Maintained by Yorktown Management & Research Co Inc” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/16/astrazeneca-plc-azn-holdings-maintained-by-yorktown-management-research-co-inc.html.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.